Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. - Wikidata - wikimedia - TriplyDB

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

http://www.wikidata.org/entity/Q39252597

about

Targeting DNA Replication Stress for Cancer Therapy Trial watch - inhibiting PARP enzymes for anticancer therapy Successes and Challenges of PARP Inhibitors in Cancer Therapy Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer PARP inhibitors in the management of breast cancer: current data and future prospects Profile of veliparib and its potential in the treatment of solid tumors 53BP1: pro choice in DNA repair Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers Targeting DNA damage response in cancer therapy Femtosecond near-infrared laser microirradiation reveals a crucial role for PARP signaling on factor assemblies at DNA damage sites.Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment Genetically engineered mouse models in oncology research and cancer medicine Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer In vivo models in breast cancer research: progress, challenges and future directions.USP28 is recruited to sites of DNA damage by the tandem BRCT domains of 53BP1 but plays a minor role in double-strand break metabolism."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells Development of synthetic lethality anticancer therapeutics.BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.PTIP associates with Artemis to dictate DNA repair pathway choice.UbcH7 regulates 53BP1 stability and DSB repair Meeting report from the second EurocanPlatform summer school on translational cancer research, Portugal, 20-24 October 2014.An update on PARP inhibitors for the treatment of cancer Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining.Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.Deciphering the BRCA1 Tumor Suppressor Network.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.Impaired 53BP1/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1.53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.Differential requirements for DNA repair proteins in immortalized cell lines using alternative lengthening of telomere mechanisms.

P2860

Q26739923-47150A06-C042-4495-8689-FF3B56D2D58E Q26745673-A2784BF9-DB9E-42D4-842F-53C261C6716E Q26777131-0B745352-BCAC-4FCF-9119-B6828E4CB21D Q26783551-79439EB8-3158-4773-9C1E-CAEF1BE35759 Q26798352-5AA92FBE-AEA7-4FFE-AC1F-3068EFFCE541 Q26801272-22C8EB38-6850-4B94-8C44-B7A654D85D8A Q26828847-0854144F-EBC4-4812-8848-88B0B3957060 Q27006938-6DB90E4D-2FC7-47A0-A089-3E2D0EB61C22 Q27023204-635B2553-9B95-4476-A82F-A992FABD6021 Q27324256-EF46D076-AC6F-4967-91E7-72CE5D3B5EB0 Q27852678-570296E7-EAF7-423F-B179-EF5A26B144CC Q28000132-62497189-E287-4BBF-8D75-81651A4850A0 Q28071345-87F8B699-4148-4F9C-A511-93ABC66D7B5B Q28075761-B028E6CD-140A-40B7-8A0B-B6DE65F8365C Q28079323-26C549AB-172F-4417-9F54-AF8565B3BE12 Q28538059-401F3036-8E84-4636-B2CB-0530CF2C95E8 Q33588117-8AB97090-4BFC-4956-B6DE-EC86908F06B2 Q33602611-00364BDA-202F-4548-91F9-DF78111D9E58 Q33618910-67119F48-D8C4-4AE5-95BE-0DE42902FE47 Q33698648-147B7638-8DE5-4589-8F1B-A0F3821A8520 Q33917649-F0278D0C-340F-4FFB-B0E0-1545272FA222 Q34221822-5C88D25F-7458-4699-A041-9CFD005808D6 Q34380368-E07975D2-23FD-4FAB-8430-C0B63D9ED83F Q34493362-28F81A23-DDA3-4371-987D-F2A5B5C98514 Q34520145-07308302-47FE-433F-AD66-76780FE73AF0 Q34697707-08201909-B9B8-4CDC-9CAE-951AB46E1438 Q34709157-3704BD68-C366-4BAB-943B-E57741E3EEEB Q35106168-E9DC250F-E231-4FC1-BA35-BEEF30269137 Q35142718-378A8239-7000-4E78-BC92-973168BDBA92 Q35656738-8F2817B3-5E8A-4719-860B-61D96D2797E4 Q35684995-ED6DC68E-B7E7-416D-A449-027435F19008 Q35812762-5F0BA496-7086-4209-97B2-F1454B5239D4 Q35845827-4BFA0CC6-BF80-45DA-B950-0A56A9E5869A Q35859458-8FA2A489-820F-4370-A109-3924B9562D4E Q35895214-E539A70B-0EDF-4106-9224-1052D89A4A54 Q35909731-E3486659-7F7C-448C-A76D-48DBFED5A435 Q36096169-83DB3F49-7196-407D-82BC-EC69E7454608 Q36129160-F324DD0F-0C4C-4434-B9FA-797B3F6BCAB2 Q36203280-3E97114B-4CCA-45CB-87F4-E52360CC172D Q36343157-0CB8260D-A532-4E42-B564-C460E8882852

P2860

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

http://www.wikidata.org/entity/Q39252597

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@en

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@nl

type

label

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@en

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@nl

prefLabel

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@en

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@nl

P1433

Q39252597-907187E8-D2E0-4E6E-A411-C8B48E65DADD

P1476

Q39252597-FDBF636C-307E-40D4-ACEC-158B1CDFF5FA

P2093

Q39252597-086F3C37-F53F-4EDF-A74F-423C25088DD2

Q39252597-0E1283FB-67C5-44EE-B0FE-ACDB58485D60

Q39252597-10D83E6E-F21B-4A75-AAB6-F7621A1F3FB0

Q39252597-126D1647-7FA2-4FA1-B8CB-297612F48007

Q39252597-2F6A52E6-1E9F-4ABF-98D0-87E94D076389

Q39252597-3A845E00-5127-450A-B2AF-12FF043405A1

Q39252597-3A9F4273-5B82-494C-87C1-920E343673DD

Q39252597-444AE331-6D46-4BB2-8000-50D0C4884AC8

Q39252597-5FD9E545-D6A6-4B8F-BE93-67229A91FA97

Q39252597-7538865A-B1CC-4A79-AA95-02D14E755D92

P304

Q39252597-B944AB8F-98AE-47CC-BE23-CF1CDC9939AE

P31

Q39252597-60A42770-A1F9-46CC-996D-883D99163D06

P356

Q39252597-81402686-BAD4-4FE8-9AF8-AB9646B7F3D6

P433

Q39252597-DAC31AEB-4252-4CEB-919A-A158F19270C7

P478

Q39252597-127DDEF5-AC4C-4CF5-9605-D8C5A472C656

P50

Q39252597-FA86D432-5F67-400B-91E9-FB8E4555889B

P577

Q39252597-C79828F6-D877-4E1E-BE02-88E2BE18FA13

P698

Q39252597-94FB0A43-A597-44DA-B0F9-C0345F9C8043

P356

2159-8290.CD-12-0049

P1433

Cancer Discovery

P1476

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

@en

P2093

Aaron Cranston

http://www.w3.org/2001/XMLSchema#string

Alan Lau

http://www.w3.org/2001/XMLSchema#string

Amal Aly

http://www.w3.org/2001/XMLSchema#string

Ariena Kersbergen

http://www.w3.org/2001/XMLSchema#string

Ellen Wientjens

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Janneke E Jaspers

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Jos Jonkers

http://www.w3.org/2001/XMLSchema#string

Liesbeth van Deemter

http://www.w3.org/2001/XMLSchema#string

P304

68-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-12-0049

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Sven Rottenberg

P577

2012-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23103855

http://www.w3.org/2001/XMLSchema#string